Lopinavir
Title: Lopinavir
CAS Registry Number: 192725-17-0
CAS Name: (aS)-N-[(1S,3S,4S)-4-[[(2,6-Dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-a-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide
Additional Names: (aS)-tetrahydro-N-[(aS)-a-[(2S,3S)-2-hydroxy-4-phenyl-3-[2-(2,6-xylyloxy)acetamido]butyl]phenethyl]-a-isopropyl-2-oxo-1(2H)-pyrimidineacetamide; (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydropyrimid-2-onyl)-3-methylbutanoyl]amino-1,6-diphenylhexane
Manufacturers' Codes: ABT-378; A-157378
Molecular Formula: C37H48N4O5
Molecular Weight: 628.80
Percent Composition: C 70.67%, H 7.69%, N 8.91%, O 12.72%
Literature References: HIV protease inhibitor; analog of ritonavir, q.v. Prepn: H. L. Sham et al., WO 9721685; idem et al., US 5914332 (1997, 1999 both to Abbott); E. J. Stoner et al., Org. Process Res. Dev. 3, 145 (1999). Protease inhibition and pharmacokinetics: H. L. Sham et al., Antimicrob. Agents Chemother. 42, 3218 (1998). In vitro metabolism study: G. N. Kumar et al., Drug Metab. Dispos. 27, 86 (1999). Pharmacokinetic enhancement by ritonavir: G. N. Kumar et al., ibid. 902. Clinical trial with ritonavir in HIV infection: S. Walmsley et al., N. Engl. J. Med. 346, 2039 (2002).
Properties: Colorless solid from ethyl acetate, mp 124-127°.
Melting point: mp 124-127°
 
Derivative Type: Mixture with ritonavir
Trademarks: Kaletra (Abbott)
 
Therap-Cat: Antiviral.
Keywords: HIV Protease Inhibitor; Antiviral; Peptidomimetics.

Others monographs:
ColchiceinePentaerythritolDanaparoidPropachlor
DifluprednateHistidineTetrachlorvinphosEcgonine
Lead BorateEthylnorepinephrine5-Methyl-3-heptanoneAmisulpride
Lead HydroxideBoric AcidOctyl CyanoacrylateToluene
©2016 DrugLead US FDA&EMEA